Publications

Search or filter publications

Search publications Search

Filter by type:

Filter by publication type

• Book
• Book chapter
• Conference paper
• Journal article
• Patent
• Report
• Software

Filter by year:

Filter from 20232022202120202019201820172016201520142013 to Filter to 20232022202120202019201820172016201520142013

---

Search results

• Conference paper
  Martinez-Gili L, McDonald JA, Liu Z, Kao DH, Allegretti JR, Barker GF, Blanco JM, Holmes E, Thursz MR, Marchesi J, Mullish BHet al., 2020,

  644 identification of novel changes in microbially-derived metabolites after fecal microbiota transplant for recurrent clostridioides difficile infection

  , Publisher: Elsevier BV, Pages: S-138-S-139, ISSN: 0016-5085
  • Publisher Web Link
  • Open Access Link
  • Cite
• Conference paper
  Ghani R, Mullish BH, McDonald JA, Ghazy A, Williams HR, Brannigan E, Satta G, Gilchrist M, Duncan N, Corbett R, Pavlu J, Innes AJ, Thursz MR, Davies F, Marchesi Jet al., 2020,

  1144 FECAL MICROBIOTA TRANSPLANT FOR MULTI-DRUG RESISTANT ORGANISMS: IMPROVED CLINICAL OUTCOMES BEYOND INTESTINAL DECOLONISATION

  , Publisher: Elsevier BV, ISSN: 0016-5085
  • Cite
• Journal article
  Blanco JM, Liu Z, Selvarajah U, Mullish BH, Alexander JL, McDonald JA, Abraham S, Marchesi Jet al., 2020,

  Sa1923 identification of new associations between psoriatic arthritis and the gut microbiota, a phenomic study

  , Gastroenterology, Vol: 158, Pages: S-481, ISSN: 0016-5085
  • Publisher Web Link
  • Cite
• Journal article
  Allegretti JR, Hurtado J, Carrellas M, Marcus J, Nemes S, Marchesi J, Mullish BH, McDonald JA, Phelps EL, Sagi S, Bohm M, Geradin Y, Silverstein M, Kelly CR, Kassam Z, Grinspan A, Fischer Met al., 2020,

  121 ULCERATIVE COLITIS PATIENTS ACHEIVE MORE ROBUST ENGRAFTMENT COMPARED TO PATIENTS WITH CROHN'S DISEASE AFTER FECAL MICROBIOTA TRANSPLANTATION FOR THE TREATMENT OF RECURRENT C. DIFFICLE INFECTION

  , Gastroenterology, Vol: 158, Pages: S-22, ISSN: 0016-5085
  • Publisher Web Link
  • Cite
• Journal article
  Chorev DS, Tang H, Rouse SL, Bolla JR, von Kugelgen A, Baker LA, Wu D, Gault J, Gruenewald K, Bharat TAM, Matthews SJ, Robinson CVet al., 2020,

  The use of sonicated lipid vesicles for mass spectrometry of membrane protein complexes

  , NATURE PROTOCOLS, Vol: 15, Pages: 1690-1706, ISSN: 1754-2189
  • Author Web Link
  • Cite
  • Citations: 25
• Journal article
  Armstrong-James D, Koh M, Ostermann M, Cockwell Pet al., 2020,

  Optimal management of acute kidney injury in critically ill patients with invasive fungal infections being treated with liposomal amphotericin B

  , BMJ CASE REPORTS, Vol: 13
  • Author Web Link
  • Cite
  • Citations: 7
• Journal article
  Furniss RCD, Kostrzewa M, Mavridou DAI, Larrouy-Maumus Get al., 2020,

  The clue is in the lipid A: Rapid detection of colistin resistance

  , PLoS Pathogens, Vol: 16, ISSN: 1553-7366
  • Publisher Web Link
  • Open Access Link
  • Cite
• Journal article
  Ritchie AI, Singanayagam A, 2020,

  Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?

  , LANCET, Vol: 395, Pages: 1111-1111, ISSN: 0140-6736
  • Author Web Link
  • Cite
  • Citations: 213
• Journal article
  Jégouzo SAF, Nelson C, Hardwick T, Wong STA, Lau NKK, Neoh GKE, Castellanos-Rueda R, Huang Z, Mignot B, Hirdaramani A, Howitt A, Frewin K, Shen Z, Fox RJ, Wong R, Ando M, Emony L, Zhu H, Holder A, Werling D, Krishnan N, Robertson BD, Clements A, Taylor ME, Drickamer Ket al., 2020,

  Mammalian lectin arrays for screening host–microbe interactions

  , Journal of Biological Chemistry, Vol: 295, Pages: 4541-4555, ISSN: 0021-9258

  Many members of the C-type lectin family of glycan-binding receptors have been ascribed roles in the recognition of microorganisms and serve as key receptors in the innate immune response to pathogens. Other mammalian receptors have become targets through which pathogens enter target cells. These receptor roles have often been documented with binding studies involving individual pairs of receptors and microorganisms. To provide a systematic overview of interactions between microbes and the large complement of C-type lectins, here we developed a lectin array and suitable protocols for labeling of microbes that could be used to probe this array. The array contains C-type lectins from cow, chosen as a model organism of agricultural interest for which the relevant pathogen–receptor interactions have not been previously investigated in detail. Screening with yeast cells and various strains of both Gram-positive and -negative bacteria revealed distinct binding patterns, which in some cases could be explained by binding to lipopolysaccharides or capsular polysaccharides, but in other cases they suggested the presence of novel glycan targets on many of the microorganisms. These results are consistent with interactions previously ascribed to the receptors, but they also highlight binding to additional sugar targets that have not previously been recognized. Our findings indicate that mammalian lectin arrays represent unique discovery tools for identifying both novel ligands and new receptor functions.

  • Abstract
  • Publisher Web Link
  • Open Access Link
  • Cite
• Journal article
  Allegretti JR, Kassam Z, Mullish BH, Chiang A, Carrellas M, Hurtado J, Marchesi JR, McDonald JAK, Pechlivanis A, Barker GF, Miguens Blanco J, Garcia Perez I, Wong WF, Gerardin Y, Silverstein M, Kennedy K, Thompson Cet al., 2020,

  Effects of fecal microbiota transplantation with oral capsules in obese patients

  , Clinical Gastroenterology and Hepatology, Vol: 18, Pages: 855-863.e2, ISSN: 1542-3565

  Background & AimsStudies in mice have shown that the intestinal microbiota can contribute to obesity via the anorexigenic gut hormone glucagon-like peptide 1 (GLP1) and bile acids, which affect lipid metabolism. We performed a randomized, placebo-controlled pilot study of the effects of fecal microbiota transplantation (FMT) in obese, metabolically uncompromised patients.MethodsWe performed a double-blind study of 22 obese patients (body mass index [BMI] ≥ 35kg/m2) without a diagnosis of diabetes, non-alcoholic steatohepatitis, or metabolic syndrome. Participants were randomly assigned (1:1) to groups that received FMT by capsules (induction dose of 30 capsules at week 4 and maintenance dose of 12 capsules at week 8) or placebo capsules. FMT capsules were derived from a single, lean donor (BMI, 17.5 kg/m2). Patients were followed through week 26; the primary outcome was safety. Stool and serum samples were collected from patients at baseline and at weeks 1, 4, 6, 8 and 12 after administration of the first dose of FMT or placebo and analyzed by 16S RNA gene sequencing. Stool and serum samples were analyzed for metabolomics by liquid chromatography-mass spectrometry. Additional outcomes were change in area under the curve for GLP1 at week 12.ResultsWe observed no significant differences in adverse events between patients who received FMT vs placebo. There was no increase in the area under the curve of GLP1 in either group. Patients who received FMT had sustained shifts in microbiomes associated with obesity toward those of the donor (P<.001). Patients who received FMT had a sustained decrease in stool levels of taurocholic acid (P<.05), compared with baseline; bile acid profiles began to more closely resemble those of the donor. We did not observe significant changes in mean BMI at week 12 in either group.ConclusionsIn a placebo-controlled pilot study, we found that FMT capsules (derived from a lean donor) were safe but did not reduce BMI in obese metabol

  • Abstract
  • Publisher Web Link
  • Open Access Link
  • Cite

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.